Beyond anti-TNF-α agents in psoriatic arthritis

Expert Review of Clinical Immunology

Volumn 9, Issue 6, 2013, Pages 507-509

  Spadaro, Antonio ^a   Lubrano, Ennio ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF MOLISE   (Italy)

Author keywords

anti IL17 monoclonal antibodies; biologic agents; IL 23 IL17 axis; psoriatic arthritis; secukinumab

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 17; INTERLEUKIN 23; PLACEBO; SECUKINUMAB;

ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DACTYLITIS; DAS28; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENTHESITIS; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; FEMALE; HUMANS; MALE;

EID: 84878714356     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.13.32     Document Type: Article

References (18)

1. McInnes IB, Sieper J, Braun J, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, Phase II proof-of-concept trial. Ann. Rheum. Dis. doi:10.1136/annrheumdis-2012-202646 (2013) (Epub ahead of print).
2. Soriano ER, McHugh NJ. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J. Rheumatol. 33(7), 1422-1430 (2006).
3. Lubrano E, Scarpa R. Psoriatic arthritis: treatment strategies using anti-inflammatory drugs and classical DMARDs. Reumatismo 64(2), 107-112 (2012).
4. Helliwell PS, Taylor WJ; CASPAR Study Group. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs -comparison of drugs and adverse reactions. J. Rheumatol. 35(3), 472-476 (2008).
5. Spadaro A, Taccari E, Mohtadi B, Riccieri V, Sensi F, Zoppini A. Life-table analysis of cyclosporin A treatment in psoriatic arthritis: comparison with other diseasemodifying antirheumatic drugs. Clin. Exp. Rheumatol. 15(6), 609-614 (1997).
6. Spadaro A, Ceccarelli F, Scrivo R, Valesini G. Life-table analysis of etanercept with or without methotrexate in patients with psoriatic arthritis. Ann. Rheum. Dis. 67(11), 1650-1651 (2008).
7. Salvarani C, Pipitone N, Marchesoni A, et al.; Italian Society for Rheumatology. Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology. Clin. Exp. Rheumatol. 29(3 Suppl. 66), S28-S41 (2011).
8. Lubrano E, Spadaro A, Marchesoni A, et al. The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept. Clin. Exp. Rheumatol. 29(1), 80-84 (2011).
9. Scarpa R, Atteno M, Lubrano E, et al. The effectiveness and safety of TNF-α blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study. Clin. Rheumatol. 30(8), 1063-1067 (2011).
10. Spadaro A, Punzi L, Marchesoni A, et al. Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study. Rheumatology (Oxford) 49(6), 1107-1111 (2010).
11. Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J. Clin. Invest. 116(5), 1218-1222 (2006).
12. Leipe J, Grunke M, Dechant C, et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum. 62(10), 2876-2885 (2010).
13. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373(9664), 633-640 (2009).
14. Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled Phase II dose-ranging study. Br. J. Dermatol. 168(2), 412-421 (2013).
15. Rich P, Sigurgeirsson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebocontrolled, Phase II regimen-finding study. Br. J. Dermatol. 168(2), 402-411 (2013).
16. Genovese MC, Durez P, Richards HB, et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a Phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann. Rheum. Dis. doi:10.1136/annrheumdis-2012-202646 (2012) (Epub ahead of print).
17. Hueber W, Patel DD, Dryja T, et al.; Psoriasis Study Group; Rheumatoid Arthritis Study Group; Uveitis Study Group. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl. Med. 2(52), 52ra72 (2010).
18. Patel DD, Lee DM, Kolbinger F, Antoni C. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann. Rheum. Dis. 72(Suppl. 2), iii116-iii123 (2013).